Sep 25 |
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions
|
Sep 20 |
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
|
Sep 16 |
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
Sep 12 |
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
|
Aug 28 |
Adaptimmune to Participate in Two Bank Conferences this September
|
Aug 15 |
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago
|
Aug 12 |
Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
|
Aug 12 |
ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload
|
Aug 12 |
Earnings summary: Adaptimmune Therapeutics beats Q2 estimates
|
Aug 12 |
Adaptimmune GAAP EPS of $0.04 beats by $0.04, revenue of $128.2M beats by $83.44M
|